Dizziness: efficient approach to treatment and prevention

The article deals with the diagnosis of dizziness as one of the most common reasons for contacting the primary care system. The term “vertigo” refers to the illusory sensation of the rotational movement of objects around the patient or the patient himself. Traditionally, the clinic distinguishes “systemic” and “non-systemic” dizziness. However, the use of these two terms “systemic” (rotational) and “non-systemic” (presyncope, imbalance caused by a violation of the neural mechanisms for maintaining balance and balance of the body and postural phobic) dizziness can make it difficult to diagnose the etiological factor due to the ambiguity of the term “non-systemic”. The most severe and painful for the patient is rotational dizziness. Most often, dizziness is caused by pathological changes in the peripheral part of the vestibular system: vestibular neuronitis, benign paroxysmal positional vertigo, Meniere’s disease. Treatment of patients with dizziness involves etiopathogenetic and symptomatic therapy. Important, from a practical point of view, is the relief of rotational dizziness itself, regardless of its etiology. A number of studies have shown the possibility of using the combined drug cinnarizine 20 mg + dimenhydrinate 40 mg in the treatment of peripheral and central vertigo. The effectiveness of therapy for dizziness with the use of a combined drug is due to the fact that one component (cinnarizine) acts mainly on peripheral structures (labyrinth), and the second (dimenhydrinate) – on central (vestibular nuclei and related centers of the brain stem) structures, providing a good vestibulolytic effect . The drug has minimal undesirable effects, which makes it possible to use it in patients of different age groups. In the article, the authors consider the effectiveness  of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg for the treatment and prevention of rotational verti go (vertigo) of various etiologies with the analysis of clinical cases.

1. Neuhauser H.K. The epidemiology of dizziness and vertigo. HandbClin Neurol. 2016;137:67–82. https://doi.org/10.1016/B978-0-444-63437-5.00005-4.

2. Hain T.C. Epidemiology of Dizziness. 2022. Available at https://dizziness-and-balance.com/disorders/dizzy_epi.html.

3. Esin R.G., Khaĭrullin I.Kh., Mukhametova E.R., Esin OR. Persistent posturalperceptual dizziness. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(4):28–33. (In Russ.) https://doi.org/10.17116/jnevro20171174128-33.

4. Xue H., Chong Y., Jiang Z.D., Liu Z.L., Ding L., Yang S.L. et al. Etiological analysis on patients with vertigo or dizziness. Zhonghua Yi Xue Za Zhi. 2018;98(16):1227–1230. https://doi.org/10.3760/cma.j.issn.0376-2491.2018.16.008.

5. Kadanka Z.Jr., Kadanka Z.S., Jura R., Bednarik J. Vertigo in Patients with Degenerative Cervical Myelopathy. J Clin Med. 2021;10(11):2496. https://doi.org/10.3390/jcm10112496.

6. Anurin I., Ziemska-Gorczyca M., Pavlovschi D., Kantor I., Dżaman K. The Impact of the Angular Head Movement’s Velocity during Diagnostic Maneuvers on Proper Benign Positional Paroxysmal Vertigo Diagnosis and Therapy. Diagnostics (Basel). 2023;13(4):665. https://doi.org/10.3390/diagnostics13040665.

7. Antonenko L.M. Drug and non-drug treatments of vertigo. Meditsinskiy Sovet. 2021;(2):39–44. (In Russ.) https://doi.org/10.21518/2079-701X-2021-2-39-44.

8. Lee H. Isolated vascular vertigo. J Stroke. 2014;16(3):124–130. https://doi.org/10.5853/jos.2014.16.3.124.

9. Brandt T., Dieterich M. Phobischer Attacken Schwankschwindel, ein neues Syndrom? Munch Med Wochenschr. 1986;128:247–250.

10. Staab J., Ruckenstein M. Chronic Dizziness and Anxiety. Arch Otolaryngol Head Neck Surg. 2005;131(8):675–679. https://doi.org/10.1001/archotol.131.8.675.

11. Staab J., Ruckenstein M. Which comes first? Psychogenic dizziness versus otogenic anxiety. The Laryngoscope. 2003;113(10):1714–1718. https://doi.org/10.1097/00005537-200310000-00010.

12. Antonenko L.M., Zastenskaya E.N. Persistent postural-perceptual dizziness: current approaches to diagnosis and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):136–140. (In Russ.) https://doi.org/10.14412/2074-2711-2019-4-136-140.

13. Staab J.P., Eckhardt-Henn A., Horii A., Jacob R., Strupp M., Brandt T., Bronstein A. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Bárány Society. J Vestib Res. 2017;27(4):191–208. https://doi.org/10.3233/VES-170622.

14. Popkirov S., Staab J.P., Stone J. Persistent postural-perceptual dizziness (PPPD): a common, characteristic and treatable cause of chronic dizziness. Pract Neurol. 2018;18(1):5–13. https://doi.org/10.1136/practneurol-2017-001809.

15. Viola P., Gioacchini F.M., Astorina A., Pisani D., Scarpa A., Marcianò G. et al. The pharmacological treatment of acute vestibular syndrome. Front Neurol. 2022;(13):999112. https://doi.org/10.3389/fneur.2022.999112.

16. Kirtane M.V., Bhandari A., Narang P., Santani R. Cinnarizine: A Contemporary Review. Indian J Otolaryngol Head Neck Surg. 2019;71(2 Suppl.):1060–1068. https://doi.org/10.1007/s12070-017-1120-7.

17. Fleming J.F. New drug effective in motion sickness. Hosp Top. 1949;27(3):26. https://pubmed.ncbi.nlm.nih.gov/18112350/.

18. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.

19. Scholtz A.W., Schwarz M., Baumann W., Kleinfeldt D., Scholtz H.J. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallelgroup clinical study. Clin Ther. 2004;26(6):866–877. https://doi.org/10.1016/s0149-2918(04)90130-0.

20. Scholtz A.W., Waldfahrer F., Hampel R., Weisshaar G. Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. Clin Drug Investig. 2022;42(9):705–720. https://doi.org/10.1007/s40261-022-01184-0.

21. Cirek Z., Schwarz M., Baumann W., Novotny M. Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo: A Double-Blind, Randomised Clinical Study. Clin Drug Investig. 2005;25(6):377–389. https://doi.org/10.2165/00044011-200525060-00003.

22. Scholtz A.W., Hahn A., Stefflova B., Medzhidieva D., Ryazantsev S.V., Paschinin A. et al. Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs BetahistineDihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial. Clin Drug Investig. 2019;39(11):1045–1056. https://doi.org/10.1007/s40261-019-00858-6.